Genitourinary Cancer News

MK-6482 appeared well-tolerated and showed promising single-agent activity among heavily pretreated patients with clear cell renal cell carcinoma, according to results of a first-in-human phase 1/phase 2 study presented at Genitourinary Cancers Symposium.

A large study of drinking habits in the oncology population revealed high rates of alcohol consumption among patients with and survivors of cancer.

A single course of adjuvant bleomycin, etoposide and cisplatin chemotherapy appeared safe and effective among a cohort of men with high-risk primary testicular cancer, according to results of the phase 3, single-arm, prospective 111 study published in European Urology.

The FDA, after reviewing more than a decade of published scientific research, reaffirmed its conclusion that there is no risk for cancer from exposure to radio waves emitted by cellphones.

Researchers at Stony Brook University’s Renaissance School of Medicine have developed an enzyme-targeting drug that could prolong survival for patients with metastatic pancreatic cancer.

Patient survival is the overarching goal of all cancer treatments, and improvements in survival that have been achieved over the years are an unequivocal victory for oncology.

Patients with myocarditis related to immune checkpoint inhibitors and either a preserved or reduced ejection fraction had a reduced global longitudinal strain, according to a study published in the Journal of the American College of Cardiology.

A regimen of bleomycin, etoposide and cisplatin for male germ cell cancer appeared associated with substantially increased risk for cardiovascular disease less than 1 year after treatment and mildly increased risk after 10 years of follow-up, according to results of a retrospective Danish study published in Journal of Clinical Oncology.

ASCO has named the refinement of surgical treatment of cancer as the Advance of the Year, recognizing emerging novel systemic therapies that changed the role of cancer surgery.

Adjuvant atezolizumab failed to extend DFS compared with observation among patients with muscle-invasive urothelial cancer, according to topline results of a randomized phase 3 trial released by the agent’s manufacturer.